Somatropin - Humatrope (Eli Lilly) - Complete Research Paper

1. Summary

Humatrope is a recombinant human growth hormone (rhGH, somatropin) manufactured by Eli Lilly and Company for the treatment of growth disorders in children and growth hormone deficiency in adults. It was one of the earliest recombinant growth hormone products, receiving FDA approval in 1987, and has an extensive clinical track record spanning nearly four decades.

FDA Approval: 1987 (Initial U.S. Approval) Manufacturer: Eli Lilly and Company

Humatrope is produced using recombinant DNA technology in Escherichia coli and contains a 191-amino acid protein identical to natural human pituitary-derived growth hormone with a molecular weight of approximately 22,125 daltons.

Key Clinical Features:

• Drug class: Recombinant human growth hormone (somatropin)
• Molecular weight: 22,125 daltons (191 amino acids)
• Administration: Subcutaneous injection
• Half-life: 3.8 hours (subcutaneous)
• Clearance: 0.18 L/hr/kg (subcutaneous)
• Dosing frequency: Daily (typically evening)
• Delivery systems: HumatroPen (reusable pen) and vials
• Generic: Not available (brand only)

Distinguishing Features: Humatrope offers flexibility in presentation with both vial formulations and cartridge systems designed for use with the HumatroPen delivery device. The cartridges come in 6 mg, 12 mg, and 24 mg strengths, allowing dosing precision across the pediatric and adult patient spectrum. Humatrope also carries an FDA-approved indication for SHOX (short stature homeobox-containing gene) deficiency, an indication not shared by all somatropin products.

Goal Archetype Integration

FDA-Approved GH vs. Secretagogues: Critical Distinction

Humatrope is pharmaceutical recombinant human growth hormone (rhGH) - fundamentally different from GH secretagogues (sermorelin, ipamorelin, CJC-1295, MK-677).

Primary Goal Alignment

When Humatrope Makes Sense

Ideal Candidates:

1. Biochemically confirmed Adult GHD - Failed GH stimulation test (insulin tolerance test, glucagon, macimorelin)

   • Childhood-onset GHD requiring adult continuation
   • Adult-onset from pituitary disease, surgery, radiation, trauma

2. SHOX deficiency diagnosis - Humatrope has specific FDA approval for this genetic condition

3. Severe symptoms despite secretagogue trial - IGF-1 remains low despite adequate GHRH/GHRP therapy

4. Non-functional pituitary - Secretagogues cannot work if somatotrophs are damaged/absent

5. Need for precise, predictable response - Direct GH allows exact dose titration

6. FDA-approved pediatric indications - GHD, Turner, PWS, SGA, ISS, SHOX deficiency

Clinical Scenarios Favoring Humatrope Over Secretagogues:

When to Choose Something Else

2. Mechanism of Action

Humatrope functions identically to natural pituitary-derived human growth hormone by binding to GH receptors on target cells throughout the body.

Primary Mechanism:

1. GH Receptor Binding: Somatropin binds to growth hormone receptors (GHR) on target cell membranes
2. Receptor Dimerization: Binding induces receptor dimerization
3. Signal Transduction: Activates JAK2-STAT5 signaling pathway
4. Gene Expression: Promotes transcription of growth-related genes
5. IGF-I Production: Stimulates hepatic synthesis of insulin-like growth factor-I (IGF-I/somatomedin C)

Growth-Promoting Effects:

• Skeletal growth: Stimulates chondrocyte proliferation and differentiation at epiphyseal growth plates
• Linear growth: Measurable increase in body length results from effects on long bone growth plates
• Muscle growth: Promotes protein synthesis and muscle mass accretion
• Organ growth: Stimulates growth of internal organs

Metabolic Effects: | System | Effect | |---

Goal Relevance:

• Help my child grow taller if they have growth hormone deficiency
• Improve my child's height if they have Turner Syndrome
• Support my child's growth if they have idiopathic short stature
• Assist with height increase for children with SHOX deficiency
• Enhance muscle growth and lean body mass
• Aid in weight loss and fat reduction
• Improve bone density and strength
• Support overall growth and development in children with growth issues

-----|--------| | Protein | Increased synthesis, nitrogen retention | | Lipid | Enhanced lipolysis, reduced adiposity | | Carbohydrate | Insulin resistance (dose-dependent) | | Mineral | Increased calcium absorption, bone turnover | | Fluid | Sodium and water retention |

Condition-Specific Effects:

In Growth Hormone Deficiency:

• Normalizes growth velocity
• Normalizes IGF-I concentrations
• Improves body composition

In Turner Syndrome:

• Promotes linear growth despite normal GH secretion
• Effects mediated through IGF-I pathway
• Results in improved adult height

In SHOX Deficiency:

• Addresses short stature caused by SHOX gene haploinsufficiency
• Improves growth velocity and final height

In Idiopathic Short Stature:

• Accelerates growth rate
• Improves predicted adult height

3. FDA-Approved Indications

Pediatric Indications:

Unique Indication - SHOX Deficiency: Humatrope is specifically approved for treatment of short stature or growth failure in children with SHOX (short stature homeobox-containing gene) deficiency whose epiphyses are not closed. This is a distinguishing indication not shared by all somatropin products.

Adult Indication:

Diagnostic Requirements:

• Childhood-onset GHD patients should be retested and biochemically confirmed as GH-deficient before continuation of therapy at adult dosage
• Adult-onset GHD requires appropriate diagnostic testing

Regulatory Status:

4. Dosing and Administration

General Principles:

• Individualize dosage based on patient response
• Divide weekly dose into daily subcutaneous injections (6-7 days/week)
• Administer preferably in evening
• Use IGF-I levels and clinical response to guide dose adjustments

Pediatric Dosing by Indication:

Adult GHD Dosing:

Weight-Based (Alternative):

• Starting: 0.006 mg/kg/day (approximately 0.04 mg/kg/week)
• May increase based on response
• Not recommended for obese patients

Non-Weight-Based (Preferred):

• Starting dose: 0.2 mg/day (range 0.15-0.30 mg/day)
• Increase by 0.1-0.2 mg/day every 1-2 months
• Adjust based on clinical response, IGF-I levels, adverse effects

Special Dosing Considerations:

• Elderly: Lower starting doses, smaller increments
• Obese: Non-weight-based dosing preferred (higher adverse effect risk)
• Women on oral estrogen: May require higher doses

Product Presentations:

Vials:

• 5 mg vials (lyophilized powder)
• Reconstitute with Diluent for Humatrope

Cartridges (for HumatroPen):

HumatroPen Device:

• Reusable pen-injector for self-administration
• Designed for specific cartridge sizes
• Use with detachable, disposable pen needles
• Never share between patients (infection transmission risk)

Reconstitution:

• Use only the diluent syringe that accompanies the cartridge
• Do not shake
• Gentle swirling to dissolve

5. Pharmacokinetics

Absorption:

• Route: Subcutaneous injection
• Bioavailability: Approximately 75% (based on similar somatropin products)
• Absorption characteristic: Slow absorption from injection site determines observed half-life

Distribution:

• Distributes to liver, kidney, muscle, bone, and other target tissues
• Pharmacokinetics similar in pediatric and adult patients
• No gender-specific differences identified

Metabolism:

• Primary: Liver and kidney (classical protein catabolism)
• Metabolized to smaller peptides and amino acids
• No significant CYP450 involvement

Elimination:

• Terminal half-life (SC): 3.8 ± 1.4 hours
• Clearance (SC): 0.18 ± 0.03 L/hr/kg

Comparison with Other Routes: The long half-life observed after subcutaneous administration (vs. IV) is due to slow absorption from the injection site (flip-flop kinetics).

Special Populations:

Pediatric vs. Adult: Pharmacokinetics of Humatrope are similar in pediatric and adult GHD patients.

Gender: Available literature indicates pharmacokinetics are similar in men and women.

Geriatric: Pharmacokinetics have not been specifically studied in patients >65 years.

Renal Impairment:

• No formal studies
• Expected reduced clearance; use with caution

Hepatic Impairment:

• No formal studies
• Liver is major site of catabolism; use with caution

6. Side Effects and Adverse Reactions

Common Adverse Events:

Adults with GHD:

Pediatric Patients:

• Injection site reactions
• Headache
• Hypothyroidism
• Mild hyperglycemia
• Lipoatrophy (rare)

Serious Adverse Reactions:

Humatrope is contraindicated in critically ill patients.

Pediatric-Specific Serious Events:

• Slipped capital femoral epiphysis (SCFE)
• Legg-Calvé-Perthes disease
• Progression of scoliosis
• Benign intracranial hypertension (pseudotumor cerebri)
• Pancreatitis (rare)

Prader-Willi Syndrome Patients: Reports of sudden death in PWS patients with:

• Severe obesity
• History of respiratory impairment
• Sleep apnea
• Respiratory infections

Metabolic Effects:

• New-onset or worsening diabetes mellitus
• Glucose intolerance
• Potential unmasking of central hypothyroidism

Long-Term Considerations:

• Carpal tunnel syndrome (may require dose reduction or surgery)
• No increased primary cancer risk demonstrated
• Theoretical concern for secondary malignancy (monitoring recommended)

7. Drug Interactions

Glucocorticoids:

• May attenuate growth-promoting effects of somatropin
• Glucocorticoid replacement therapy may require dose adjustment
• Carefully monitor growth response in patients on corticosteroids

Thyroid Hormones:

• Somatropin may unmask central hypothyroidism
• May require initiation of thyroid hormone replacement
• Monitor thyroid function regularly
• Untreated hypothyroidism impairs somatropin response

Insulin and Oral Antidiabetics:

Sex Steroids:

Oral Estrogen:

• Oral estrogen increases SHBG
• May reduce IGF-I response
• Women on oral estrogen may need higher somatropin doses
• Consider transdermal estrogen as alternative

Androgens:

• May enhance growth response
• Monitor for virilization

Cytochrome P450 Substrates: Somatropin may affect CYP450-mediated drug metabolism:

• CYP3A4 substrates: Monitor for reduced efficacy
• Corticosteroids, sex steroids, anticonvulsants, cyclosporin: Consider level monitoring

Other Growth Hormone Products:

• Do not use concurrently with other GH products
• No benefit; increased adverse effect risk

8. Contraindications

Absolute Contraindications:

1. Acute critical illness due to:

   • Complications following open heart surgery
   • Abdominal surgery
   • Multiple accidental trauma
   • Acute respiratory failure

2. Active malignancy

   • Discontinue if evidence of recurrent tumor activity

3. Pediatric patients with closed epiphyses (for growth promotion)

4. Prader-Willi syndrome with:

   • Severe obesity
   • History of upper airway obstruction
   • Sleep apnea
   • Severe respiratory impairment

5. Known hypersensitivity to somatropin or any excipients

6. Active proliferative or severe non-proliferative diabetic retinopathy

Warnings and Precautions:

9. Special Populations

Pediatric Use:

• Safety and efficacy established for approved pediatric indications
• Dosing varies by indication
• Monitor growth response, bone age, IGF-I
• Watch for SCFE (hip/knee pain, limping)
• Monitor scoliosis in at-risk patients

Geriatric Use:

• Limited data in patients ≥65 years
• May be more sensitive to somatropin effects
• Start with lower doses
• Use smaller dose increments
• Monitor more frequently

Pregnancy:

• No adequate studies in pregnant women
• Use only if clearly needed
• Animal studies: No evidence of teratogenicity at appropriate doses

Lactation:

• Unknown if excreted in human milk
• Caution advised
• Consider risk-benefit

Renal Impairment:

• No formal studies
• CKD patients may receive somatropin
• Monitor carefully; reduced clearance expected

Hepatic Impairment:

• No formal studies
• Liver is major metabolic site
• Use with caution

Obesity:

• Obese patients more likely to experience adverse effects
• Non-weight-based dosing recommended
• Higher risk for carpal tunnel syndrome, edema

Turner Syndrome:

• May have increased pancreatitis risk
• Monitor for cardiovascular abnormalities
• Otitis media common
• May have increased scoliosis risk

10. Monitoring Parameters

Baseline Assessment:

Ongoing Monitoring:

Growth Parameters (Pediatric):

Laboratory Monitoring:

Clinical Monitoring:

Dose Adjustment Triggers:

• IGF-I above normal: Decrease dose
• IGF-I below normal: Consider increase
• Adverse effects: Reduce dose
• Poor response: Evaluate compliance, thyroid function

11. Cost and Availability

Pricing (United States, 2024-2025):

Annual Cost Estimates:

• Pediatric patients: $12,000-$40,000/year (dose-dependent)
• Adult patients: $10,000-$30,000/year (dose-dependent)
• Without insurance: $500-$7,500/month

Generic/Biosimilar Status:

• Generic: Not available (brand only)
• Biosimilar: No FDA-approved biosimilar in US
• Humatrope remains brand-name only

Insurance Coverage:

• Coverage varies by plan and diagnosis
• Prior authorization typically required
• Step therapy may be required
• Medicare: Limited coverage
• Commercial insurance: Variable

Patient Assistance Programs:

Humatrope Co-Pay Card (Eli Lilly):

Ineligible for Co-Pay Card:

• Medicare, Medicaid, TRICARE beneficiaries
• VA, DoD patients
• State/federal program participants

Other Assistance:

• Eli Lilly Patient Assistance Program
• PAN Foundation (income-based)
• Humatrope Reimbursement Center
• Prescription Hope ($70/month fixed)

12. Clinical Evidence Summary

Clinical Development: Humatrope has nearly 40 years of clinical experience since FDA approval in 1987, with extensive data supporting efficacy and safety across approved indications.

Pediatric GHD:

• Significant improvement in height velocity
• First-year growth rates of 10+ cm/year (vs. baseline ~4 cm/year)
• Improved adult height outcomes
• Long-term safety established

Turner Syndrome:

• Adult height gains of 5-8 cm above predicted
• Optimal response with early initiation
• Higher doses (up to 0.375 mg/kg/week) may be needed

SHOX Deficiency:

• Specific indication distinguishing Humatrope
• Improved growth velocity
• Enhanced predicted adult height
• Well-tolerated at 0.35 mg/kg/week

Idiopathic Short Stature:

• Mean adult height increase of 4-5 cm
• Response varies among individuals
• Best outcomes with early treatment

Small for Gestational Age:

• Significant catch-up growth achievable
• Many patients reach normal height range
• Higher doses permitted (up to 0.47 mg/kg/week)

Adult GHD:

• Improved body composition
• Increased lean mass, decreased fat mass
• Enhanced quality of life
• Improved exercise capacity

Safety Database:

• Extensive post-marketing surveillance
• No increased primary cancer risk
• Adverse effects generally manageable with dose adjustment
• Known risks (SCFE, carpal tunnel, glucose intolerance) well-characterized

13. Comparison with Alternatives

Comparison of FDA-Approved Somatropin Products:

Humatrope Distinguishing Features:

Device Comparison:

• HumatroPen: Reusable pen, cartridge-based
• Genotropin MiniQuick: Single-use, prefilled
• Norditropin FlexPro: Pre-filled, room temp stable
• Omnitrope Pen: Reusable, lower cost

When to Choose Humatrope:

1. SHOX deficiency indication
2. Patient/provider familiarity with Humatrope
3. Preference for cartridge-based reusable pen
4. Access to Eli Lilly copay programs
5. Need for multiple cartridge size options

Switching Considerations:

• All somatropin products therapeutically equivalent
• Device training required when switching
• Dosing similar across products
• Insurance formulary may drive selection

14. Storage and Handling

Storage Conditions:

Before Reconstitution:

After Reconstitution:

Room Temperature Limits:

• Do not leave at room temperature more than 30 minutes per day
• Avoid freezing reconstituted product

Reconstitution Instructions:

Vials (5 mg):

1. Use Diluent for Humatrope provided
2. Direct stream against vial wall
3. Swirl gently; do not shake
4. Inspect for clarity before use

Cartridges (6, 12, 24 mg):

1. Use only accompanying diluent syringe
2. Follow HumatroPen instructions
3. Do not shake
4. Inspect for clarity

Handling Precautions:

• Wash hands before handling
• Clean injection site with alcohol
• Rotate injection sites
• Never share HumatroPen between patients
• Use pen needles only once
• Dispose properly in sharps container

Travel Guidelines:

• Keep refrigerated in insulated cooler
• Do not freeze
• Protect from extreme temperatures
• Carry physician letter for international travel

15. References

1. Humatrope Prescribing Information. Eli Lilly and Company. 2025. Available at: https://pi.lilly.com/us/humatrope-pi.pdf

2. FDA Label Reference ID: 5621635. Humatrope (somatropin) for injection. 2025. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/019640s111lbl.pdf

3. DailyMed. HUMATROPE- somatropin kit. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a774e1ae-3997-49ee-8b0e-99a2b315d409

4. Drugs.com. Humatrope: Uses, Dosage, Side Effects, Warnings. Available at: https://www.drugs.com/humatrope.html

5. Humatrope HCP Portal - Dosing & Pen Selection. Eli Lilly. Available at: https://humatrope.lilly.com/hcp/dosing

6. GoodRx. Humatrope 2025 Prices, Coupons & Savings Tips. Available at: https://www.goodrx.com/humatrope

7. SingleCare. Humatrope Coupons 2025. Available at: https://www.singlecare.com/prescription/humatrope

8. Humatrope Patient Support & Resources. Eli Lilly. Available at: https://humatrope.lilly.com/patient-support

9. RxList. Humatrope (Somatropin rDNA Origin): Side Effects, Uses, Dosage. Available at: https://www.rxlist.com/humatrope-drug.htm

10. Drugs.com. Humatrope Prices, Coupons, Copay Cards & Patient Assistance. Available at: https://www.drugs.com/price-guide/humatrope

Document compiled from FDA prescribing information, manufacturer resources, and clinical literature. Last updated: December 2024.

Status: PAPER 69 OF 76 COMPLETE

Next Paper: #70 - Somatropin (Norditropin)